Search Results

You are looking at 1 - 10 of 305 items for :

  • "targeted agents" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Targeted Agents: Management of Dermatologic Toxicities

Barbara Burtness

assortment of adverse skin effects are associated with the use of epidermal growth factor receptor (EGFR) inhibitors such as cetuximab and erlotinib. Although papulopustular rash may be the most commonly observed side effect of these targeted agents, non

Full access

Clinical Treatment Decisions for Advanced Renal Cell Cancer

Toni K. Choueiri

For the treatment of advanced renal cell cancer (RCC), 7 targeted agents have been approved in less than 8 years, which has greatly extended progression-free survival (PFS; Table 1 ). As even more targeted agents emerge from the pipeline, the

Full access

Clinical Discussion and Review of the Management of Brain Metastases

Priscilla K. Brastianos, William T. Curry, and Kevin S. Oh

, which must be further investigated. 80 Table 2 Prospective Trials of Targeted Agents in Brain Metastases The role of bevacizumab is also being explored. In a small case series of 4 patients with central nervous system metastases from

Full access

Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma

Leo I. Gordon

response rate was 87%, which Dr. Gordon called “fairly exciting data in a small number of patients, most of whom were naïve to brentuximab vedotin.” However, he noted, there were few CRs (17%). Table 1. Targeted Agents in Hodgkin Lymphoma

Full access

Treatment of Metastatic Pancreatic Cancer

Andrew H. Ko and Margaret A. Tempero

Pancreatic adenocarcinoma represents the fourth-leading cause of cancer-related mortality in the United States. The vast majority of patients are diagnosed at advanced stages of the disease when surgery is no longer an option. For these patients, systemic therapy remains the mainstay of care. Although single-agent gemcitabine has remained the standard of care since its approval in 1997, improvements in patient outcomes may potentially be realized by (1) applying pharmacokinetic principles to optimize drug delivery, such as the administration of gemcitabine at a “fixed-dose rate” infusion; (2) combining gemcitabine with other cytotoxic agents for which evidence of synergy exists, such as platinum compounds; and (3) integrating novel targeted agents such as bevacizumab, erlotinib, and cetuximab into treatment paradigms, based on an increasing understanding of the molecular pathways that govern pancreatic tumor growth and maintenance. This article provides the evidence to support each of these approaches and highlights future directions in the management of metastatic pancreatic cancer.

Full access

Combining Systemic Therapy With Radiation: Head and Neck Cancer Treatments in an Era of Targeted Agents and Immunotherapy

Harish N. Vasudevan and Sue S. Yom

of cisplatin, details of RT, and patient and tumor characteristics, will be important to guide more precise treatment regimens for individual patients. Alternatives to Cisplatin: Second-Line Cytotoxic Therapies, Targeted Agents, and Immunotherapy

Full access

Emerging Multimodality Approaches to Treat Localized Esophageal Cancer

Ronan J. Kelly

, eliminate micrometastatic disease, and increase pCR, which is a surrogate of long-term survival. 37 Table 2. Ongoing Trials Investigating HER2-Targeted Agents or Checkpoint Inhibitors CheckMate 577 ( ClinicalTrials.gov identifier: NCT02743494 ) is studying

Full access

Targeted Strategies in the Treatment of Metastatic Colon Cancer

Diane Reidy and Leonard Saltz

malignancies [abstract] . J Clin Oncol 2003 ; 22 ( Suppl 1 ): Abstract 817 . 25. Saltz LB Perez-Soler R . Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005 ; 23 : 5235 – 5246 . 26

Full access

Practice-Changing Interventions in the Systemic Management of Breast Cancer

Presented by: William J. Gradishar

Breast cancer mortality is approximately half of what it was in 1980 due to aggressive screening, combination adjuvant therapies, and the emergence of effective targeted agents for the metastatic setting. “We anticipate that as data emerge from

Full access

Emerging Therapies in the Treatment of Bladder Cancer

Presented by: Arlene O. Siefker-Radtke

Therapy Enfortumab Vedotin “Following this frontline standard, we now have multiple targeted agents,” commented Dr. Siefker-Radtke. She began by discussing enfortumab vedotin, which was the first antibody–drug conjugate to be approved for the